Loading…
Evaxion A/S is projected to rise to $3.35 by 2027, a +6% move from its current price of $3.17. EVAX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $3.06 | $3.17 | $3.28 | -0.04% |
| Jul 14 | $3.02 | $3.17 | $3.33 | -0.08% |
| Jul 15 | $2.98 | $3.17 | $3.36 | -0.12% |
| Jul 16 | $2.95 | $3.17 | $3.39 | -0.15% |
| Jul 17 | $2.93 | $3.16 | $3.42 | -0.19% |
| Jul 18 | $2.91 | $3.16 | $3.44 | -0.23% |
| Jul 19 | $2.88 | $3.16 | $3.46 | -0.27% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.88 | $3.16 | $3.46 | -0.27% |
| Week 2 | $2.77 | $3.15 | $3.59 | -0.54% |
| Week 3 | $2.68 | $3.14 | $3.69 | -0.80% |
| Week 4 | $2.61 | $3.14 | $3.77 | -1.07% |
| Week 5 | $2.55 | $3.13 | $3.84 | -1.34% |
| Week 6 | $2.49 | $3.12 | $3.90 | -1.60% |
| Week 7 | $2.44 | $3.11 | $3.96 | -1.87% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Evaxion A/S is a clinical-stage biotech company that develops artificial intelligence-powered immunology vaccines. Its programs include EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its vaccines also include pre-clinical programs EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S.
aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Evaxion A/S trades as a healthcare stock with a current price of $3.17 and a market capitalization of $26.44M. Its rank stands at 4768 among listed entities. The symbol for the asset is EVAX.
These figures place Evaxion A/S in the small-cap segment of the healthcare sector as of now. The forecast suggests a near-term neutral path with a longer-term bullish trajectory, reflected in gradual upside from 2031 onward.
A major floor 24.6% below — a decisive break under it would weaken the trend.
The nearest floor, 3.8% below — buyers have tended to step in here.
The nearest ceiling, 29.3% above — a clean break opens room to run.
A major ceiling 44.2% above — clearing it would confirm fresh momentum.
Key EVAX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of EVAX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.26 | Sell | $3.23 | Sell |
| MA 10 | $3.23 | Sell | $3.26 | Sell |
| MA 20 | $3.31 | Sell | $3.35 | Sell |
| MA 50 | $3.76 | Sell | $3.60 | Sell |
| MA 100 | $3.76 | Sell | $3.81 | Sell |
| MA 200 | $4.49 | Sell | $4.18 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.85 | Neutral |
| Stoch RSI (14) | 44.64 | Neutral |
| CCI (20) | -67.13 | Neutral |
| Williams %R (14) | -75.76 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | -6.49 | Sell |
| Bollinger %B (20,2) | 0.29 | Neutral |
| Stochastic %K (14) | 24.24 | Neutral |
| TRIX (15) | -0.69 | Sell |
| Awesome (5,34) | -0.28 | Sell |
| Ultimate (7,14,28) | 53.25 | Neutral |
| Momentum (10) | 0.03 | Buy |
| Aroon Osc (25) | -40.00 | Sell |
| Hull MA (9) | 3.22 | Sell |
| ADX (14) | 16.77 | Neutral |
| ATR (14) | 0.11 | Info |
The 30-day technical picture is NEUTRAL, with RSI14 at 40. The stock trades below the SMA50 of $3.76 and below the SMA200 of $4.49, indicating limited near-term upside. Key support is identified at $3.05 and resistance at $4.10. Over the last 30 days, the price has ranged from a low of $2.52 to a high of $3.98.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.91 | $3.17 | $4.05 | 0% | Neutral | |
| $2.60 | $3.35 | $4.61 | +6% | Neutral | |
| $2.69 | $3.59 | $5.16 | +13% | Neutral | |
| $2.25 | $3.10 | $4.62 | -2% | Neutral | |
| $2.35 | $3.33 | $5.10 | +5% | Neutral | |
| $2.81 | $4.07 | $6.40 | +28% | Bullish | |
| $3.07 | $4.56 | $7.34 | +44% | Bullish | |
| $3.31 | $5.02 | $8.25 | +58% | Bullish | |
| $3.19 | $4.94 | $8.27 | +56% | Bullish | |
| $3.08 | $4.87 | $8.29 | +54% | Bullish | |
| $4.29 | $7.44 | $13.62 | +135% | Bullish | |
| $5.16 | $10.56 | $21.48 | +233% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.91 | $3.17 | $3.88 | +0.00% |
| August 2026 | $2.66 | $3.16 | $3.88 | -0.23% |
| September 2026 | $2.55 | $3.06 | $3.80 | -3.23% |
| October 2026 | $2.60 | $3.14 | $3.94 | +2.49% |
| November 2026 | $2.64 | $3.21 | $4.08 | +2.32% |
| December 2026 | $2.58 | $3.16 | $4.05 | -1.63% |
Click any year to see its month-by-month EVAX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The EVAX price prediction for 2026 points to an average of $3.17 (low $2.91, high $4.05) — a potential gain of 0% on today's $3.17. A consolidation phase looks the most probable path here.
In 2027, EVAX is projected to trade between $2.60 and $4.61, averaging $3.35 — a potential gain of +6% from today's $3.17. That is up +6% on the projected 2026 average. Price action looks broadly range-bound.
Evaxion A/S's 2028 outlook centres on $3.59, within a $2.69 to $5.16 range. That is up +7% on the projected 2027 average. That marks a +13% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, EVAX could reach as high as $4.62, with a base case around $3.10 and support toward $2.25 — roughly -2% from $3.17. Price action looks broadly range-bound.
Expect EVAX to range from $2.35 to $5.10 through 2030. The $3.33 average target implies a +5% move from current prices. That is up +7% on the projected 2029 average. A consolidation phase looks the most probable path here.
The EVAX price prediction for 2031 points to an average of $4.07 (low $2.81, high $6.40) — a potential gain of +28% on today's $3.17. Momentum favours further upside here.
In 2032, EVAX is projected to trade between $3.07 and $7.34, averaging $4.56 — a potential gain of +44% from today's $3.17. That is up +12% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Evaxion A/S's 2033 outlook centres on $5.02, within a $3.31 to $8.25 range. That is up +10% on the projected 2032 average. That marks a +58% change versus current levels. Momentum favours further upside here.
By 2034, EVAX could reach as high as $8.27, with a base case around $4.94 and support toward $3.19 — roughly +56% from $3.17. Buyers look set to stay in control over this stretch.
Expect EVAX to range from $3.08 to $8.29 through 2035. The $4.87 average target implies a +54% move from current prices. That is -2% versus the projected 2034 average. Momentum favours further upside here.
The EVAX price prediction for 2040 points to an average of $7.44 (low $4.29, high $13.62) — a potential gain of +135% on today's $3.17. Buyers look set to stay in control over this stretch.
In 2050, EVAX is projected to trade between $5.16 and $21.48, averaging $10.56 — a potential gain of +233% from today's $3.17. That is up +42% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in EVAX today (≈ 315.457413 EVAX) could be worth
$3,332.76
+$2,332.76 (+233%) by 2050 · US Dollar
Based on the average projected EVAX price of $10.56 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in EVAXwould be worth at today's price.
$1,000 invested in EVAX on Jul 10, 2025 (≈ 387.596911 EVAX) would be worth
$1,228.68
+$228.68 (+22.9%) today · 1.23× · US Dollar
Based on a EVAX entry price of $2.58 vs. today's $3.17.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.41 | $929.62 | -7.0% |
| 1 month ago | $3.79 | $836.41 | -16.4% |
| 3 months ago | $4.04 | $784.65 | -21.5% |
| 6 months ago | $5.18 | $611.97 | -38.8% |
| 1 year ago | $2.58 | $1,228.68 | +22.9% |
| All time (5.0y) ago | $307 | $10.33 | -99.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our EVAX forecast.
Our base-case forecast reaches $6.30 around 2040.
Implied market cap at $6.30: $52.54M
The multi-year forecast shows near-term flat to modest movement in 2026 (avg $3.17) and 2027 (avg $3.36) with respective ROIs of 0 and 5.9%, followed by 2028 (avg $3.59, ROI 13.1%) and 2029 (avg $3.10, ROI -2.3%). In 2030, the average is forecast at $3.33 with ROI 5.2%. The outlook turns bullish from 2031 onward, with 2031 avg $4.07 (ROI 28.5%), 2032 avg $4.56 (ROI 43.8%), 2033 avg $5.03 (ROI 58.6%), 2034 avg $4.94 (ROI 55.9%), and 2035 avg $4.86 (ROI 53.3%).
The bullish trajectory continues with 2040 avg $7.43 (ROI 134.4%) and 2050 avg $10.57 (ROI 233.3%). These figures are estimates and not guarantees, and actual results depend on multiple factors.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $3.33 with a min of $2.36 and a max of $5.11; ROI is 5.2% and sentiment is NEUTRAL.
Near term (2026–2029) is NEUTRAL, with 2026 avg $3.17 and 2027 avg $3.36 (ROI 5.9%), 2028 avg $3.59 (ROI 13.1%), and 2029 avg $3.10 (ROI -2.3%). From 2031 onward, the forecast is BULLISH with higher averages and ROIs (2031 avg $4.07, ROI 28.5%; 2032 avg $4.56, ROI 43.8%; 2050 max $21.48). These are estimates, not guarantees.
Yes. The forecast shows a path to higher prices with 2040 max $13.61 and 2050 max $21.48; the 2050 average is $10.57 with a bullish outlook (ROI 233.3%).
The current price is $3.17 and the market capitalization is $26.44M.
The 30-day range low is $2.52 and the high is $3.98.
Evaxion A/S Community Discussion
0Share your Evaxion A/S price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.